Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05230771 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 1, 2022 (before its estimated March 1, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Start date: Mar 1, 2022 to Apr 1, 2022v3
  2. Primary completion date: Feb 1, 2024 to Mar 1, 2024
    • Study completion date: Feb 1, 2027 to Mar 1, 2027
    • Start date: Feb 1, 2022 to Mar 1, 2022
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This single-center, prospective study was conducted to investigate the efficacy and safety of palliative surgery after translational therapy in the treatment of metastatic gastric cancer. The primary endpoint was 2-year overall survival (OS) rate. Secondary endpoints were median OS, progression-free survival (PFS), 1-year OS, adverse events (AE), severe AE, the quality of life (QOL) and treatment cost.
Trial Details
NCT Number NCT05230771
Lead Sponsor Fujian Medical University
Conditions
(from sponsor)		 Metastatic Gastric Cancer, Surgery, Chemotherapy
Related terms Stomach Neoplasms
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov